Financial Summary


PDS Biotechnology Corporation

PDS Biotechnology Corporation (PDSB)

$2.94
0 (0.00%)
-
-
Market Info
Financial Info
Financial Modelling
Symbol PDSB
Price 2.94$
Beta 0.00
Volume Avrg. 1.95M
Market Cap 0.05B
Shares (2019) 4,868.08K
Last Div 0
Dividend Yield -
DCF Unlevered -
DCF Levered -
ROE -59.83% Strong Sell
ROA -48.30% Strong Sell
Operating Margin -Infinity% Strong Sell
Debt / Equity 23.88% Neutral
P/E -1.82 Sell
P/B 1.09 Strong Buy

Income Statement

Quarter data

Balance Sheet Statement

Quarter data
Year 2019 2018 2017 2016 2015
Short-term debt 2.27-3.08--
Other Assets -----
Total current liabilities 8.596.6812.876.382.79
Cash and cash equivalents 130.19106.4088.0734.6512.16
Long-term debt 3.0314.9517.38--
Cash and short-term investments 130.19106.4088.0734.6512.16
Total debt 5.3014.9520.46--
Inventories -----
Deferred revenue -----
Goodwill and Intangible Assets -----
Total non-current liabilities 3.0314.9517.38--
Total non-current assets 2.823.563.570.570.02
Total liabilities 11.6221.6430.256.382.79
Total assets 134.09110.9192.6236.2214.49
Other comprehensive income 184.72190.34214.31222.6440.63
Short-term investments -----
Property, Plant & Equipment Net 2.773.423.420.430.02
Net Debt -124.89-91.45-67.61-34.65-12.16
Investments -----
Total shareholders equity 122.4889.2862.3729.8411.70
Retained earnings (deficit) -62.25-101.07-151.95-192.82-28.94
Long-term investments -----
Receivables -----
Payables 2.583.474.370.401.20
Total current assets 131.27107.3589.0535.6514.47

Cash Flow Statement

Quarter data
Year 2019 2018 2017 2016 2015
Operating Cash Flow -21.75-32.19-40.70-33.15-18.07
Free Cash Flow -23.06-32.88-40.89-33.15-18.07
Capital Expenditure 1.310.690.19--
Depreciation & Amortization 0.250.270.320.300.10
Acquisitions and disposals -----
Deferred income taxes ----0.38
Investment purchases -----
Accounts payables -0.071.420.90-3.97-1.98
Sales/Maturities of investments -----
Change in working capital --22.01-24.48-46.92-17.59
Debt repayment -0.53-1.49--20.00-
Other non-cash items -----
Investing Cash Flow -1.31-0.69-0.19-29.38
Cash at beginning of period 13.73130.19106.4088.07-
Stock-based compensation 2.905.316.187.473.14
Net cash flow / Change in cash 116.46-23.79-18.33-53.4212.16
Effect of forex changes on cash -----
Financing Cash Flow 139.529.0822.55-20.270.75
Dividend payments -----
Accounts receivables -----
Cash at end of period 130.19106.4088.0734.6512.16
Net cash provided by operating activities -21.75-32.19-40.70-33.15-18.07
Other working capital 122.68100.6776.1929.2711.68
Inventory -----

Retained Earning Schedule

Year 2015 2016 2017 2018 2019
Retained Earnings (Previous Year) --62-101-152-193
Net Income -28-39-51-41-7
Stock Dividends -34--0-171
Dividend Paid -----
Retained Earnings -62-101-152-193-29

PPE Schedule

Year 2015 2016 2017 2018 2019
Gross PPE -3330
Annual Depreciation 1-0-0-3-0
Capital Expenditure 110--
Net PPE 33300

Intangible and Goodwill Schedule

Year 2015 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) -----
New Purchases -----
Intangible and Goodwill -----

About


Dr. Frank K. Bedu-Addo
Healthcare
Biotechnology
NasdaqGS

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial, a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104 (TRP2) for the treatment of melanoma. The company has a collaboration agreement with Merck & Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer. The company is based in Princeton, New Jersey.